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Responses and adverse effects of carboplatin-based 
chemotherapy for pediatric intracranial germ cell 
tumors
Purpose: Cisplatin-based chemotherapy has been commonly used for 
the treatment of intracranial germ cell tumors (IC-GCTs). However, this 
treatment exhibits some adverse effects such as renal problems and 
hearing difficulty. Carboplatin-based chemotherapy was administered 
to pediatric patients with IC-GCTs from August 2004 at the Samsung 
Medical Center. In this study, we assessed the responses and adverse 
effects of carboplatin-based chemotherapy in pediatric IC-GCTs 
patients according to the risk group, and compared the results with 
those of the previous cisplatin-based chemotherapy.
Methods: We examined 35 patients (27 men and 8 women) diagnosed 
with IC-GCTs between August 2004 and April 2008 and received risk-
adapted carboplatin-based chemotherapy at the Samsung Medical 
Center. Patients were divided into either low-risk (LR) or high-risk (HR) 
groups and a retrospective analysis was performed using information 
from the medical records.
Results: Although hematological complications were common, hearing 
difficulties or grade 3 or 4 creatinine level elevation were not observed 
in patients who underwent carboplatin-based chemotherapy. The 
frequency of febrile neutropenia did not differ between the risk groups. 
The overall survival was 100% and event-free survival (EFS) was 95.7 
%. The EFS rate was 100% in the LR group and 90% in the HR group, 
respectively.
Conclusion: Despite their common occurrence in high-risk patients, no 
lethal hematological complications were associated with carboplatin-
based treatment. The current carboplatin-based chemotherapy 
protocol is safe and effective for the treatment of pediatric patients with 
IC-GCTs.
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Introduction
Intracranial germ cell tumors (IC-GCTs) are lesions that develop 
in patients of all ages. They vary in their geographic incidence and 
in Japan and the Far East, the incidence of germ cell tumors is five 
to eightfold greater than that in Western societies
1). In 2002, Cho 
et al.
2) reported that the frequency of IC-GCTs was 11.2% in 677 
Korean pediatric patients with brain tumors and in 2009, Goodwin 
et al.
3) reported that the incidence was 2.6 per million in the Asian 
population. The age distribution of affected patients is unimodal; 
there is an abrupt surge in frequency during the early pubertal years; 
68% of patients are diagnosed between 10 and 21 years of age
4). 
Cisplatin-based chemotherapy has been commonly used for the 
treatment of IC-GCTs
5, 6). However, in 2005, You et al.
7) reported the 
results of cisplatin-based chemotherapy in patients with IC-GCTs 
diagnosed at the Samsung Medical Center from October 2002 to 
December 2003 and the limitations of cisplatin-based chemotherapy. 
For preventing cisplatin-associated toxicities, carboplatin-based 
chemotherapy has been used for pediatric patients with IC-GCTs 
from August 2004 at our center. In 2010, Yoo et al.
8) reported the 
effectiveness of risk adapted carboplatin-based chemotherapy for 
patients with malignant central nervous system-GCT. Some experts 
have recommended that more intensive chemotherapy is more 
beneficial for high-risk patients
9). However, there are no studies on the 
responses and toxicities of carboplatin-based chemotherapy in Korea, 
and no analysis of toxicity associated with risk groups. Therefore, in 
this study, the responses to carboplatin-based chemotherapy were 
assessed and the toxicities according to risk group were evaluated.
Materials and methods
1. Patients
Thirty-five patients who were diagnosed with IC-GCTs from 
August 2004 to April 2008 and received chemotherapy at Samsung 
Medical Center were included in this study. All patients except one had 
a surgical biopsy before chemotherapy was started. When histological 
confirmation was not done before the chemotherapy, magnetic 
resonance imaging (MRI) findings along with elevated tumor 
marker(s) such as α -fetoprotein (AFP) and/or β -human chorionic 
gonadotropin (β -HCG) were used for the diagnosis. Evaluations 
using brain MRI, whole spine MRI, cerebrospinal fluid (CSF) cytology, 
and tumor marker levels in the serum and CSF were performed in all 
patients prior to the initiation of chemotherapy. The patients were divided 
into either low-risk (LR) or high-risk (HR) groups. The LR criteria were 
defined as follows: 1) pure germinoma confirmed by histology, 2) normal 
AFP level, and 3) a low serum and CSF β -HCG level (<50 mIU/mL). 
All of the others that did not meet any of the LR criteria were regarded 
as HR; some patients with a histologically proven germinoma had an 
elevated AFP and high β -HCG levels, which suggested they actually 
had nongerminomatous components at sites that were not biopsied.
2. Treatments
After biopsy, four cycles of chemotherapy were administered, 
followed by radiotherapy (RT). A risk-adapted carboplatin-based 
regimen (carboplatin, etoposide, cyclophosphamide, bleomycin) 
was implemented and bleomycin was used only in the HR patient 
group. In addition, in the high risk group, a double-dose carboplatin 
was used (LR group 450 mg/m
2/day for 1 day, HR group 450 mg/
m2/day for 2 days). The regimens were composed of two different 
schedules alternating every three weeks and were completed after 
four cycles (Fig. 1). All patients received RT. A radiological oncologist 
individualized the RT dose for each patient before RT.
3. Methods
 A retrospective review of the patient medical records including 
age, gender, weight loss, symptoms (fever, nausea, vomiting, auditory 
symptoms), blood tests (nadirs of leukocyte/absolute neutrophil count 
(ANC)/hemoglobin/platelet/albumin, peak levels of total bilirubin/ 
aspartate aminotransferase (AST)/alanine aminotransferase (ALT) 
/creatinine), numbers of red blood cell and platelet transfusion, 
primary site of the tumor, and the histological findings were recorded. 
Pure tone audiometry and speech audiometry were used for hearing 
examinations. The toxicities were assessed according to the National 
Cancer Institute Common Terminology Criteria for Adverse Events 
(NCI CTC version 3.0)
10).
4. Statistics
Fisher’s exact test and the Chi-square test were used for a com-
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parison of the frequencies and observed values between the study 
groups. The Mann-Whitney U-test and Kruskal-Wallis test were 
used for non-parametric statistical analysis to evaluate the difference 
between the groups. For the survival analysis, Kaplan-Meier analysis 
was used. The data were analyzed using SPSS (version 12.0, SPSS 
Inc, Chicago, IL, USA) and a P-value less than 0.05 was considered 
significant.
Results
The patients’ clinical/pathological characteristics are detailed in 
Table 1. The median patient age was 15.5 years (range, 6.4‒26.2 
years) and the median follow up period was 23 months (range, 4‒49 
months). The hematological toxicities were the most common. The 
overall frequency of grade 3 or 4 hematological toxicity was in the 
following order: neutropenia (100%), thrombocytopenia (91.4%), 
and anemia (54.3%). However, there was no significant difference in 
the hematological toxicities except for anemia between the LR group 
and the HR group. A Grade 3 or 4 anemia was 33.3% in the LR 
group and 85.7% in the HR group (P<0.01).
Febrile neutropenia (85.7%) was the third most common in pa-
tients treated with carboplatin-based chemotherapy. There was 
no difference in the frequency of febrile neutropenia between the 
LR group and the HR group. The frequency of microbiologically 
documented infection (MDI) was five in the HR group (P<0.01). 
However, there was no mortality associated with a MDI. Grade 3 or 
4 creatinine elevation was not present in any of the patients. Pure tone 
audiometry  and speech audiometry after 4 cycles of chemotherapy 
was assessed in seven patients and all seven patients had normal 
findings. Hearing difficulty was not found in any of the patients who 
received carboplatin-based chemotherapy (Table 2).
 In an analysis of continuous variables associated with toxicity, 
he  matological parameters such as nadirs of leukocyte/hemoglobin/
ANC/platelet showed lower values in the HR group. The patients in 
the HR group had longer chemotherapy intervals than the patients in 
the LR group (P<0.01). The nadir of albumin and peak levels of total 
bilirubin/AST/ALT/and creatinine were not different between the LR 
group and the HR group. However, the patients in the HR group had 
more weight loss during the treatment period. The mean percentage 
of weight loss in the LR group was 4.8±4.9%, and in the HR group 
it was 12.1±8.7% (P<0.01). Red blood cell and platelet transfusions 
were more frequent in the HR group (P<0.01). The overall survival 
(OS) rate was 100% and the event free survival (EFS) rate was 95.7% 
(Fig. 2). The EFS rate was 100% in the LR group, and 90% in the 
Table 1. Characteristics of Intracranial Germ Cell Tumor Patients
Variables
Patients
Number %
Sex
Male 27 77.1
Female 8 22.9
Risk group
Low 21 60.0
High 14 40.0
Tumor location
Pineal (P) 12 34.3
Sellar or Suprasellar (S) 10 28.6
Thalamus (T) or basal ganglia (BG) 6 17.1
Ventricle (V) 1 2.8
P+S 3 8.6
Multiple 3 8.6
Histology
Germinoma (G) 29 82.8
Choriocarcinoma (CC) 1 2.9
Immature Teratoma (IT) 1 2.9
Mature Teratoma (MT) 1 2.9
G+IT 2 5.6
Unknown (biopsy not performed)* 1 2.9
*Unknown one patient had typical magnetic resonance imaging scan 
findings along with elevated CSF α-fetoprotein level (695 ng/mL, normal level 
<20 ng/mL)
Table 2. Grade 3 or 4 Toxicities of Intracranial Germ Cell Tumor Patients
Toxicities
Patients No. (%)
Total Low Risk High Risk P-value
Hematologic
Leukocyte 35 (100) 21 (100) 14 (100) NS
ANC 35 (100) 21 (100) 14 (100) NS
Platelet 32 (91.4) 18 (85.7) 14 (100) NS
Hemoglobin 19 (54.3) 7 (33.3) 12 (85.7) 0.005
Infection
Febrile neutropenia 30 (85.7) 18 (85.7) 12 (85.7) NS
MDI* 5 (14.3) 0 (0) 5 (35.7) 0.006
Gastrointestinal
Nausea 6 (17.1) 2 (9.5) 4 (28.6) NS
Vomiting 5 (14.3) 2 (9.5) 3 (21.4) NS
Weight loss 3 (8.6) 1 (4.8) 2 (14.3) NS
Hepatobiliary
AST 2 (5.7) 1 (4.8) 1 (7.1) NS
ALT 3 (8.6) 2 (9.5) 1 (7.1) NS
Hypoalbuminemia 0 (0) 0 (0) 0 (0) NS
Hyperbilirubinemia 0 (0) 0 (0) 0 (0) NS
Renal
Cystitis 0 (0) 0 (0) 0 (0) NS
Creatinine 0 (0) 0 (0) 0 (0) NS
Ototoxicity
Hearing loss 0 (0) 0 (0) 0 (0) NS
Abbreviations: No., number; ANC, absolute neutrophil count; MDI,   
microbiologically documented infection; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; NS, nonspecific.
*Identified organisms: Candida tropicalis, Candida glabrata, Klebsiella 
pneumoniae, Staphylococcus aureus, Escherichia coli, Enterococcus 
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HR group (Fig. 3). One patient in the high risk group had tumor 
recurrence and he is under treatment again.
Discussion
Platinum-based chemotherapy is commonly used in patients 
with IC-GCTs.  The leading platinum compounds used in cancer 
chemotherapy are cisplatin, carboplatin and oxaliplatin. They share 
some structural similarities. However, there are marked differences 
among them in therapeutic use, pharmacokinetics and adverse effect 
profiles. Cisplatin is the most highly protein bound, followed by 
oxaliplatin and carboplatin; the degree of protein binding is related to 
adverse responses
11). It appears to be superior to carboplatin in terms of 
therapeutic effectiveness (germ cell tumors, bladder cancer, and head 
and neck cancer)
12, 13), however, it has some severe associated toxicity 
such as ototoxicity and nephrotoxicity.
In 1994, Allen et al.
14) reported the effect of carboplatin in patients 
with newly diagnosed germinomas of the central nervous system. In 
2002, Stern et al.
15) suggested carboplatin could be used to substitute 
for cisplatin during the treatment of pediatric germ cell tumors and 
in 2005, You et al.
7) reported results of a cisplatin-based treatment of 
pediatric patients with IC-GCTs at the Samsung Medical Center 
and the limitations of cisplatin-based chemotherapy. The EFS rate in 
the LR group treated with cisplatin-based chemotherapy was 100% 
and for the HR group it was 88.9%. The EFS rates were similar to 
the results of current study. However, four of nine patients in the high 
risk group had hearing difficulty and had a diagnosis of sensorineural 
hearing loss. In this study, seven patients had pure tone audiometry 
and speech audiometry by otology experts; none of the patients 
treated with carboplatin-based chemotherapy had sensorineural 
hearing loss. And grade 3 or 4 creatinine elevation was not found 
in patients treated with carboplatin-based chemotherapy, even in 
HR group patients who received double-dose carboplatin-based 
chemotherapy. In addition, there was no significant cystitis identified 
in any of the patients treated with carboplatin-based chemotherapy. 
And Yoo et al.
8) recommended carboplatin-based chemotherapy in 
patients with central nervous system-GCTs because many patients 
may have signs of diabetes insipidus. Cisplatin may not be appropriate 
for patients with diabetes insipidus because they must be managed 
by strict input/output measurements along with adequate hydration 
and desmopressin replacement. Considering the immature renal and 
hearing function of pediatric patients, carboplatin can be the useful 
agent for pediatric patients with IC-GCTs.
In contrast to cisplatin, myelotoxicity represents the most 
pro    minent adverse effect of carboplatin. Carboplatin induced 
myelosuppresion is dose-related and results in thrombocytopenia 
and neutropenia
11). In this study, the HR group patients received a 
double-dose carboplatin and needed more frequent RBC and platelet 
transfusions. The neutrophil recovery was also delayed in HR group 
patients. Myelosuppression is closely related to infection, which is 
a major cause of morbidity and mortality in cancer patients
16). The 
probability of developing MDI, when a child presents with fever 
and therapy-induced neutropenia, ranges from 10 to 40%
17-20). 
However, cisplatin can also induce myelosuppression and febrile 
neutropenia. You et al.
7) reported that the frequency of grade 4 
neutropenia associated with cisplatin-based chemotherapy was 
100% and the frequency of grade 3 or 4 infectious complication was 
80% in the LR group, 100% in the HR group. In 2007, Okamoto 
et al.
21) compared the effects of carboplatin and cisplatin in patients 
with small cell lung cancer. They reported a high percentage of 
neu  tropenia in the carboplatin group (95%) and cisplatin group 
(90%). However, there was no difference in infection prevalence 
between the carboplatin group and cisplatin group (P=0.78). In this 
study, grade 3 or 4 neutropenia was 100% and grade 3 or 4 febrile 
neutropenia was 85.7%. In addition, five patients in the HR group 
Fig. 2. The 5-year overall survival (OS) (100%) and event-free survival 
(EFS) (95.7%) of 35 patients.
Fig. 3. Event-free survival (EFS) rate for LR group (100%) and for HR 
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had a MDI. However, all infections were controlled by antibiotic 
treatment and supportive care with no sequelae. No complication or 
mortality associated with infection occurred in patients treated with 
carboplatin-based chemotherapy.
In conclusion, carboplatin-based chemotherapy used for the treat-
ment of IC-GCTs is safer and more effective than we expected for 
the treatment of pediatric patients with IC-GCTs. There was no 
significant nephrotoxicity and ototoxicity in the patients treated with 
carboplatin-based chemotherapy. Although hematological toxicities 
were frequent in the HR group of patients, there were no lethal 
complications associated with the carboplatin-based treatment. A 
multicenter prospective, multivariate study is required to determine 
the long-term efficacy and feasibility of the current protocol.
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